



ASX ANNOUNCEMENT

27 July 2023

## CHIMERIC RECEIVES PATENT ALLOWANCE FOR CHLOROTOXIN IN JAPAN

**Sydney, Australia, 27 July 2023:** Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the Japan Patent Office has issued a Notice of Allowance for application JP2022007016A, which covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinical stage CAR NK asset CHM 1301.

Initial patent protection for CLTX CAR technology in Japan was granted in 2022 under patent number JP 7,085,990. The newly allowed application, JP2022007016A, expands the scope of patent protection to cover a broader range of CLTX CAR construct designs.

Chimeric holds the exclusive worldwide license to develop and commercialize JP2022007016A, under patent number JP 7,085,990, and related patent applications filed in other global territories.

According to IQVIA, Japan is now the third largest pharmaceutical market in the world and the second ranked country by protected pharmaceutical brand spend. Innovative specialty products in the country are reporting double-digit compound growth, and the availability and use of biologics continues to expand.<sup>1</sup>

Chimeric’s CEO and Managing Director Jennifer Chow said: “We are delighted to see our patent protection for CLTX CAR therapies broadened in Japan, the third largest pharmaceutical market in the world, where CAR T cell therapies for blood cancers have already been successfully commercialized. The grant of this key Japan patent will further expand the robust intellectual property portfolio underpinning our CLTX CAR pipeline assets.”

<sup>1</sup> <https://www.iqvia.com/blogs/2022/10/finding-japanese-healthcare-insights-in-minutes-not-months>

### ABOUT CHIMERIC THERAPEUTICS:

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy



pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Initial positive data from the investigator-initiated phase 1A trial has been presented on patients treated in the first two dose levels of the trial.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase 1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

## **CONTACT**

### Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper  
Executive Chairman  
Chimeric Therapeutics  
T: + 61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)